Third Quarter Revenues of $455.6 million, up 2.7% Versus Prior Year Period; up 3.1% on Constant Currency Basis

Third Quarter GAAP Diluted EPS of $1.40, up 10.2% Over the Prior Year Period

Third Quarter Adjusted Diluted EPS of $1.80, up 12.5%

Updated 2016 Guidance Ranges for GAAP Revenue Growth from 3.0% to 4.0% to 2.4% to 2.8% and Constant Currency Revenue Growth from 5.0% to 6.0% to 3.4% to 3.8%

Reaffirmed 2016 Guidance Range for GAAP Diluted EPS of $5.34 to $5.41

Increased 2016 Guidance Range for Adjusted Diluted EPS from $7.20 to $7.32 to $7.25 to $7.34

Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 25, 2016.

Third quarter 2016 net revenues were $455.6 million, an increase of 2.7% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, third quarter 2016 net revenues increased 3.1% over the year ago period.

Third quarter 2016 GAAP diluted earnings per share from continuing operations increased 10.2% to $1.40, as compared to $1.27 in the prior year period. Third quarter 2016 adjusted diluted earnings per share from continuing operations increased 12.5% to $1.80, compared to $1.60 in the prior year period.

“Third quarter sales were below our expectations, driven in part by weakness in certain Asian emerging markets, continued softness in oil-based Latin American economies, the timing of distributor purchases which negatively impacted some of our North American product lines and a slower than initially anticipated contribution from revenue associated with new products,” said Benson Smith, Chairman and Chief Executive Officer. “Despite the softness in revenue, non-revenue dependent financial leverage allowed the Company's adjusted earnings per share performance in the third quarter to exceed our expectations."

Added Smith, "Based on the performance during the third quarter, as well as our expectations for the remainder of the year, we are lowering our full year 2016 GAAP and constant currency revenue growth ranges. We now expect our full year 2016 GAAP and constant currency revenue to grow between 2.4% to 2.8% and 3.4% to 3.8%, respectively. Despite the reduction in revenue growth expectations, we are maintaining our full year GAAP earnings per share range of $5.34 to $5.41 and increasing our full year adjusted earnings per share range to be $7.25 to $7.34."

THIRD QUARTER NET REVENUE BY SEGMENT

The following table provides information regarding net revenues in each of the Company's reportable operating segments and all of its other operating segments for the three months ended September 25, 2016 and September 27, 2015 on both a GAAP and constant currency basis. The discussion below the table of the principal factors behind changes in net revenues for the three months ended September 25, 2016 as compared to the prior year period applies to both GAAP revenue and constant currency revenue, although GAAP revenue also was affected by foreign currency exchange rate fluctuations, as indicated in the "Foreign Currency" column of the table.

        Three Months Ended % Increase/ (Decrease)

September 25,

2016

   

September 27,

2015

Constant

Currency

   

Foreign

Currency

   

Total

Change

(Dollars in millions) Vascular North America $ 85.1 $ 82.6 3.0 % — 3.0 % Surgical North America 41.9 39.6 5.7 % (0.1 )% 5.6 % Anesthesia North America 48.7 47.6 2.2 % — 2.2 % EMEA 121.4 120.9 2.2 % (1.7 )% 0.5 % Asia 64.0 61.9 2.1 % 1.4 % 3.5 % OEM 41.4 39.0 6.3 % — 6.3 % All Other   53.1   52.1 2.8 % (0.8 )% 2.0 % Total $ 455.6 $ 443.7 3.1 % (0.4 )% 2.7 %  

Vascular North America third quarter 2016 net revenues were $85.1 million, an increase of 3.0% compared to the prior year period on both a GAAP and constant currency basis. The constant currency increase in revenue was largely due to an increase in new product sales and price increases.

Surgical North America third quarter 2016 net revenues were $41.9 million, an increase of 5.6% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, third quarter 2016 net revenues increased 5.7% compared to the prior year period. The constant currency increase in revenue was largely due to an increase in new product sales and price increases.

Anesthesia North America third quarter 2016 net revenues were $48.7 million, an increase of 2.2% compared to the prior year period on both a GAAP and constant currency basis. The constant currency increase in revenue was largely due to an increase in new product sales.

EMEA third quarter 2016 net revenues were $121.4 million, an increase of 0.5% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, third quarter 2016 net revenues increased 2.2% compared to the prior year period. The constant currency increase in revenue was largely due to higher sales volumes of both existing and new products.

Asia third quarter 2016 net revenues were $64.0 million, an increase of 3.5% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, third quarter 2016 net revenues increased 2.1% compared to the prior year period. The constant currency increase in revenue was largely due to price increases.

OEM and Development Services (“OEM”) third quarter 2016 net revenues were $41.4 million, an increase of 6.3% compared to the prior year period on both a GAAP and constant currency basis. The constant currency increase in revenue was largely due to higher sales volumes of existing products and revenues generated by acquired businesses.

OTHER FINANCIAL HIGHLIGHTS AND KEY PERFORMANCE METRICS

Depreciation expense, amortization of intangible assets and deferred financing charges for the first nine months of 2016 aggregated $96.3 million compared to $92.0 million for the prior year period.

Cash and cash equivalents at September 25, 2016 were $499.5 million compared to $338.4 million at December 31, 2015.

Net accounts receivable at September 25, 2016 were $261.8 million compared to $262.4 million at December 31, 2015.

Net inventories at September 25, 2016 were $341.8 million compared to $330.3 million at December 31, 2015.

2014 MANUFACTURING FOOTPRINT REALIGNMENT PLAN

In April 2014, our Board of Directors approved a restructuring plan (the "2014 Manufacturing Footprint Realignment Plan") involving the consolidation of operations and a related reduction in workforce at certain facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the second quarter 2014 and were initially expected to be substantially completed by the end of 2017.

To date, we have completed the consolidation and relocation of a significant portion of the operations subject to the 2014 Manufacturing Footprint Realignment Plan, and estimate that we will achieve annualized savings of approximately $17 million by the end of 2016 directly related to these actions. With respect to the remaining actions to be taken under the plan, we revised our savings, expense and timing estimates during the third quarter of 2016 to reflect the impact of changes we have implemented with respect to medication delivery devices included in certain kits primarily sold by our Vascular North America operating segment and, to a lesser extent, certain kits primarily sold by our Anesthesia North America operating segment. As a result of these changes, we have reduced our estimate with respect to the overall annualized savings we expect to realize under the plan from our prior estimate of $28 million to $35 million to a range of $23 million to $27 million. We anticipate that this decrease in projected savings will be offset, in large part, by an expected increase in annual revenues resulting from improved pricing on the affected Vascular kits directly related to the changes described above. We anticipate that this projected increase in annual revenues, taken together with the projected annualized savings we expect to realize under the 2014 Manufacturing Footprint Realignment Plan, should enable us to improve our pre-tax income on an annualized basis by approximately $28 million to $33 million once the plan has been completed.

As a result of the changes described above, we also revised our estimates with respect to the charges we expect to incur in connection with the plan. Specifically, we now estimate that we will incur $43 million to $48 million in aggregate pre-tax charges associated with the 2014 Manufacturing Footprint Realignment Plan, compared to our prior estimate of approximately $37 million to $44 million. In addition, we expect cash outlays associated with the plan to be in the range of $33 million to $38 million, compared to our prior estimate of approximately $26 million to $31 million. We continue to expect to incur $24 million to $30 million in aggregate capital expenditures under the plan.

We currently expect that the 2014 Manufacturing Footprint Realignment Plan will be substantially complete by the end of the first half of 2020 rather than the end of 2017, which we previously anticipated.

We currently are evaluating the feasibility of alternative measures designed to mitigate the loss of expected savings and accelerate the currently estimated timetable for completion of the plan.

2016 OUTLOOK

The Company lowered its previous estimate that revenue for full year 2016 would increase 3.0% to 4.0% over prior year revenue on a GAAP basis; the Company now expects full year 2016 revenue to increase 2.4% to 2.8% over prior year revenue on a GAAP basis. The Company also lowered its previous estimate that revenue for full year 2016 would increase 5.0% to 6.0% over prior year revenue on a constant currency basis; the Company now expects full year 2016 revenue to increase 3.4% to 3.8% over prior year revenue on a constant currency basis.

The Company reaffirmed its full year 2016 GAAP diluted earnings per share from continuing operations guidance range of $5.34 to $5.41. This estimate represents an increase of 8.8% to 10.2% over 2015 GAAP diluted earnings per share. In addition, the Company increased its full year 2016 adjusted diluted earnings per share from continuing operations guidance from a range of $7.20 to $7.32 to a range of $7.25 to $7.34. This new estimate represents an increase of 14.5% to 16.0% over 2015 adjusted earnings per share and reflects our expectation that foreign currency exchange rate fluctuations will have an approximately neutral impact on adjusted earnings per share for 2016.

       

FORECASTED 2016 CONSTANT CURRENCY REVENUE GROWTH RECONCILIATION

 

 

Low     High   Forecasted 2016 GAAP revenue growth 2.4 % 2.8 %   Estimated impact of foreign currency fluctuations   1.0 %       1.0 %   Forecasted 2016 constant currency revenue growth   3.4 %       3.8 %    

FORECASTED 2016 ADJUSTED EARNINGS PER SHARE RECONCILIATION

  Low     High   Diluted earnings per share attributable to common shareholders $ 5.34 $ 5.41   Restructuring, impairment charges and special items, net of tax $ 0.84 $ 0.85   Intangible amortization expense, net of tax $ 0.98 $ 0.99   Amortization of debt discount on convertible notes, net of tax $ 0.09       $ 0.09     Adjusted diluted earnings per share $ 7.25       $ 7.34    

CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION

As previously announced, Teleflex will comment on its financial results on a conference call to be held today at 8:00 a.m. (ET). The call will be available live and archived on the company’s website at www.teleflex.com and the accompanying presentation will be posted prior to the call. An audio replay will be available until November 1, 2016 at 11:59pm (ET), by calling 855-859-2056 (U.S./Canada) or 404-537-3406 (International), Passcode: 97714633.

ADDITIONAL NOTES

References in this release to the impact of foreign currency on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions.

In the discussion of segment results, "new products" refers to products we have sold for 36 months or less, and "existing products" refers to products we have sold for more than 36 months.

Certain financial information is presented on a rounded basis, which may cause minor differences.

Segment results and commentary exclude the impact of discontinued operations.

NOTES ON NON-GAAP FINANCIAL MEASURES

This press release includes certain non-GAAP financial measures, which include:

Adjusted diluted earnings per share. This measure excludes, depending on the period presented (i) restructuring and other impairment charges; (ii) certain losses and other charges, including, for 2016, charges related to facility consolidations and contingent consideration liabilities, net of the gain on sale of assets and, for 2015, charges related to acquisition and integration costs, and charges related to facility consolidations, net of the gain on sale of assets and reversal of charges related to contingent consideration and a litigation verdict against the Company with respect to a non-operating joint venture; (iii) amortization of the debt discount on the Company’s convertible notes; (iv) intangible amortization expense; (v) loss on extinguishment of debt; and (vi) tax benefits resulting primarily from the resolution of audits of prior year returns and tax law changes affecting the Company's deferred tax liability. In addition, the calculation of diluted shares within adjusted earnings per share gives effect to the anti-dilutive impact of the Company’s convertible note hedge agreements, which reduce the potential economic dilution that otherwise would occur upon conversion of the Company’s senior subordinated convertible notes (under GAAP, the anti-dilutive impact of the convertible note hedge agreements is not reflected in diluted shares).

Constant currency revenue growth. This measure excludes the impact of translating the results of international subsidiaries at different currency exchange rates from period to period.

Management believes these measures are useful to investors because they eliminate items that do not reflect Teleflex’s day-to-day operations. In addition, management believes that the calculation of non-GAAP diluted shares is useful to investors because it provides insight into the offsetting economic effect of the convertible note hedge against conversions of the convertible notes. Management uses these financial measures for internal managerial purposes, when publicly providing guidance on possible future results, and to assist in our evaluation of period-to-period comparisons. These financial measures are presented in addition to results presented in accordance with generally accepted accounting principles (“GAAP”) and should not be relied upon as a substitute for GAAP financial measures. Tables reconciling historical adjusted diluted earnings per share to historical GAAP earnings per share are set forth below. Tables reconciling constant currency net revenues to GAAP net revenues and reconciling forecasted non-GAAP measures to the most directly comparable forecasted GAAP measures are set forth above.

 

RECONCILIATION OF CONSOLIDATED STATEMENT OF INCOME ITEMS

Dollars in millions, except per share amounts

  Quarter Ended - September 25, 2016    

Cost of goods

sold

   

Selling, general

and

administrative

expenses

   

Research and

development

expenses

   

Restructuring

and other

impairment

charges

   

(Gain) loss on

sale of business

and assets

   

Interest

expense, net

    Income taxes    

Net income

(loss)

attributable to

common

shareholders

from

continuing

operations

   

Diluted

earnings per

share available

to common

shareholders

   

Shares used

in calculation

of GAAP

and adjusted

earnings per

share

GAAP Basis $214.0 $139.8 $15.1 $3.0 ($2.8 ) $12.8 $7.5 $66.2 $1.40 47,446 Adjustments Restructuring and other impairment charges — — — 3.0 — — 1.0 2.1 $0.04 — Losses and other charges, net (A) 4.2 0.8 0.0 — (2.8 ) — 0.8 1.5 $0.03 — Amortization of debt discount on convertible notes — — — — — 1.1 0.4 0.7 $0.02 — Intangible amortization expense — 16.0 0.1 — — — 3.7 12.4 $0.26 — Tax adjustment (B) — — — — — — 0.3 (0.3 ) ($0.01 ) — Shares due to Teleflex under note hedge (C) — — — — — — — — $0.06 (1,463 ) Adjusted basis $209.8 $123.0 $14.9 — — $11.7 $13.7 $82.6 $1.80 45,983   Quarter Ended - September 27, 2015

Cost of goods

sold

Selling, general

and

administrative

expenses

Research and

development

expenses

Restructuring

and other

impairment

charges

(Gain) loss on

sale of business

and assets

Interest

expense, net

Income taxes

Net income

(loss)

attributable to

common

shareholders

from

continuing

operations

Diluted

earnings per

share available

to common

shareholders

Shares used

in calculation

of GAAP

and adjusted

earnings

per share

GAAP Basis $215.5 $138.8 $12.6 $0.7 ($0.4 ) $14.2 $0.8 $61.5 $1.27 48,532 Adjustments Restructuring and other impairment charges — — — 0.7 — — 0.3 0.4 $0.01 — Losses and other charges, net (A) 2.3 (0.5 ) — — (0.4 ) — 0.8 0.6 $0.01 — Amortization of debt discount on convertible notes — — — — — 3.3 1.2 2.1 $0.04 — Intangible amortization expense — 15.5 — — — — 4.1 11.4 $0.23 — Tax adjustment (B) — — — — — — 3.9 (3.9 ) ($0.08 ) — Shares due to Teleflex under note hedge (C) — — — — — — — — $0.11 (3,536 ) Adjusted basis $213.2 $123.9 $12.6 — — $10.8 $11.1 $72.1 $1.60 44,996  

(A) In 2016, losses and other charges, net related primarily to facility consolidations, somewhat offset by the gain on sale of assets. In 2015, losses and other charges, net related primarily to facility consolidations, somewhat offset by reversals of charges related to contingent consideration liabilities and a gain on sale of assets.

(B) The tax adjustment represents a net benefit resulting primarily from (1) the resolution of audits of prior year returns and (2) tax law changes affecting our deferred tax liability.

(C) Adjusted diluted shares are calculated by giving effect to the anti-dilutive impact of the Company’s convertible note hedge agreements, which reduce the potential economic dilution that otherwise would occur upon conversion of the Company's convertible notes. Under GAAP, the anti-dilutive impact of the convertible note hedge agreements is not reflected in diluted shares.

 

RECONCILIATION OF CONSOLIDATED STATEMENT OF INCOME ITEMS

Dollars in millions, except per share amounts

  Year-to-date Ended - September 25, 2016    

Cost of

goods sold

   

Selling, general

and

administrative

expenses

   

Research and

development

expenses

   

Restructuring

and other

impairment

charges

   

(Gain) loss

on sale of

business and

assets

   

Interest

expense,

net

   

Loss on

extinguishment of

debt, net

   

Income

taxes

   

Net income (loss)

attributable to

common

shareholders

from continuing

operations

   

Diluted earnings

per share

available to

common

shareholders

   

Shares used in

calculation of

GAAP and

adjusted

earnings per

share

GAAP Basis $630.9 $419.1 $42.9 $12.9 ($4.2 ) $38.3 $19.3 $18.1 $176.3 $3.69 47,824 Adjustments Restructuring and other impairment charges — — — 12.9 — — — 3.4 9.5 $0.20 — Losses and other charges, net (A) 10.9 2.7 0.1 — (4.2 ) — — 3.6 5.9 $0.12 — Amortization of debt discount on convertible notes — — — — — 6.0 — 2.2 3.8 $0.08 — Intangible amortization expense — 47.2 0.3 — — — — 12.1 35.4 $0.74 — Loss on extinguishment of debt, net — — — — — — 19.3 7.0 12.2 $0.26 — Tax adjustment (B) — — — — — — — 5.8 (5.8 ) ($0.12 ) — Shares due to Teleflex under note hedge (C) — — — — — — — — — $0.25 (2,253 ) Adjusted basis $620.1 $369.3 $42.5 — — $32.2 — $52.2 $237.3 $5.21 45,571   Year-to-date Ended - September 27, 2015

Cost of

goods sold

Selling, general

and

administrative

expenses

Research and

development

expenses

Restructuring

and other

impairment

charges

(Gain) loss

on sale of

business and

assets

Interest

expense,

net

Loss on

extinguishment of

debt, net

Income

taxes

Net income (loss)

attributable to

common

shareholders

from continuing

operations

Diluted earnings

per share

available to

common

shareholders

Shares used in

calculation of

GAAP and

adjusted

earnings per

share

GAAP Basis $641.1 $420.8 $38.9 $5.7 ($0.4 ) $47.2 $10.5 $15.4 $145.4 $3.03 47,969 Adjustments Restructuring and other impairment charges — — — 5.7 — — — 2.1 3.6 $0.08 — Losses and other charges, net (A) 7.6 (3.0 ) — — (0.4 ) — — 2.2 1.9 $0.03 — Amortization of debt discount on convertible notes — — — — — 9.8 — 3.6 6.2 $0.13 — Intangible amortization expense — 45.3 — — — — — 12.0 33.3 $0.69 — Loss on extinguishment of debt, net — — — — — — 10.5 3.8 6.6 $0.14 — Tax adjustment (B) — — — — — — — 4.1 (4.1 ) ($0.08 ) — Shares due to Teleflex under note hedge (C) — — — — — — — — — $0.30 (3,319 ) Adjusted basis $633.5 $378.5 $38.9 — — $37.4 — $43.1 $193.0 $4.32 44,650  

(A) In 2016, losses and other charges, net related primarily to facility consolidations and charges related to contingent consideration liabilities, somewhat offset by the gain on sale of assets. In 2015, losses and other charges, net related primarily to acquisition and integration costs, and charges related to facility consolidations, somewhat offset by reversals of charges related to contingent consideration liabilities, a litigation verdict against the Company with respect to a non-operating joint venture and the gain on sale of assets.

(B) The tax adjustment represents a net benefit resulting primarily from (1) the resolution of audits of prior year returns and (2) tax law changes affecting our deferred tax liability.

(C) Adjusted diluted shares are calculated by giving effect to the anti-dilutive impact of the Company’s convertible note hedge agreements, which reduce the potential economic dilution that otherwise would occur upon conversion of the Company's convertible notes. Under GAAP, the anti-dilutive impact of the convertible note hedge agreements is not reflected in diluted shares.

ABOUT TELEFLEX INCORPORATED

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck® - trusted brands united by a common sense of purpose.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements, including, but not limited to, forecasted 2016 GAAP and constant currency revenue growth and GAAP and adjusted diluted earnings per share. Actual results could differ materially from those in the forward-looking statements due to, among other things, conditions in the end markets we serve, customer reaction to new products and programs, our ability to achieve sales growth, price increases or cost reductions; changes in the reimbursement practices of third party payors; our ability to realize efficiencies and to execute on our strategic initiatives; changes in material costs and surcharges; market acceptance and unanticipated difficulties in connection with the introduction of new products and product line extensions; product recalls; unanticipated difficulties in connection with the consolidation of manufacturing and administrative functions, including as a result of difficulties with various employees, labor representatives or regulators; the loss of skilled employees in connection with such initiatives; unanticipated difficulties, expenditures and delays in complying with government regulations applicable to our businesses; the impact of government healthcare reform legislation; our ability to meet our debt obligations; changes in general and international economic conditions, including fluctuations in foreign currency exchange rates and the impact of the United Kingdom's vote to leave the European Union; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2015.

 

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

    Three Months Ended   Nine Months Ended

September 25,2016

 

September 27,2015

September 25,2016

 

September 27,2015

(Dollars and shares in thousands, except per share) Net revenues $ 455,648   $ 443,714 $ 1,354,094   $ 1,325,189 Cost of goods sold   214,046     215,501     630,946     641,102   Gross profit 241,602 228,213 723,148 684,087 Selling, general and administrative expenses 139,797 138,840 419,128 420,765 Research and development expenses 15,067 12,571 42,892 38,898 Restructuring charges 3,027 660 12,876 5,688 Gain on sale of assets   (2,776 )   (408 )   (4,173 )   (408 ) Income from continuing operations before interest, extinguishment of debt and taxes 86,487 76,550 252,425 219,144 Interest expense 12,888 14,306 38,579 47,685 Interest income (115 ) (130 ) (324 ) (453 ) Loss on extinguishment of debt   —     —     19,261     10,454   Income from continuing operations before taxes 73,714 62,374 194,909 161,458 Taxes on income from continuing operations   7,514     803     18,134     15,415   Income from continuing operations   66,200     61,571     176,775     146,043   Operating income (loss) from discontinued operations 260 (788 ) (116 ) (1,432 ) (Benefit) taxes on income (loss) from discontinued operations   138     (69 )   (119 )   180   Income (loss) from discontinued operations   122     (719 )   3     (1,612 ) Net income 66,322 60,852 176,778 144,431

Less: Income from continuing operations attributable to noncontrolling interest

  —     28     464     692   Net income attributable to common shareholders $ 66,322   $ 60,824   $ 176,314   $ 143,739   Earnings per share available to common shareholders: Basic: Income from continuing operations $ 1.50 $ 1.48 $ 4.09 $ 3.50 Income (loss) from discontinued operations   0.01     (0.02 )   —     (0.04 ) Net income $ 1.51   $ 1.46   $ 4.09   $ 3.46   Diluted: Income from continuing operations $ 1.40 $ 1.27 $ 3.69 $ 3.03 Loss from discontinued operations   —     (0.02 )   —     (0.03 ) Net income $ 1.40   $ 1.25   $ 3.69   $ 3.00   Dividends per share $ 0.34 $ 0.34 $ 1.02 $ 1.02 Weighted average common shares outstanding Basic 44,045 41,597 43,081 41,542 Diluted 47,446 48,532 47,824 47,969 Amounts attributable to common shareholders: Income from continuing operations, net of tax $ 66,200 $ 61,543 $ 176,311 $ 145,351 Income (loss) from discontinued operations, net of tax   122     (719 )   3     (1,612 ) Net income $ 66,322   $ 60,824   $ 176,314   $ 143,739      

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

   

September 25,2016

 

December 31,2015

(Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 499,459 $ 338,366 Accounts receivable, net 261,833 262,416 Inventories, net 341,830 330,275 Prepaid expenses and other current assets 34,354 34,915 Prepaid taxes 22,259 30,895 Assets held for sale   4,137   6,972 Total current assets 1,163,872 1,003,839 Property, plant and equipment, net 322,019 316,123 Goodwill 1,305,078 1,295,852 Intangible assets, net 1,164,644 1,199,975 Investments in affiliates 27 152 Deferred tax assets 2,792 2,341 Other assets   43,237   53,492 Total assets $ 4,001,669 $ 3,871,774 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 181,895 $ 417,350 Accounts payable 70,246 66,305 Accrued expenses 68,972 64,017 Current portion of contingent consideration 7,539 7,291 Payroll and benefit-related liabilities 81,746 84,658 Accrued interest 12,611 7,480 Income taxes payable 11,271 8,059 Other current liabilities   18,122   8,960 Total current liabilities 452,402 664,120 Long-term borrowings 849,967 641,850 Deferred tax liabilities 311,390 315,983 Pension and postretirement benefit liabilities 131,222 149,441 Noncurrent liability for uncertain tax positions 26,693 40,400 Other liabilities   60,073   48,887 Total liabilities 1,831,747 1,860,681 Commitments and contingencies Total common shareholders' equity 2,169,922 2,009,272 Noncontrolling interest   —   1,821 Total equity   2,169,922   2,011,093 Total liabilities and equity $ 4,001,669 $ 3,871,774    

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

    Nine Months Ended

September 25, 2016

 

September 27, 2015

(Dollars in thousands) Cash flows from operating activities of continuing operations: Net income $ 176,778 $ 144,431 Adjustments to reconcile net income to net cash provided by operating activities: Loss (income) from discontinued operations (3 ) 1,612 Depreciation expense 40,272 34,035 Amortization expense of intangible assets 47,486 45,278 Amortization expense of deferred financing costs and debt discount 8,506 12,662 Loss on extinguishment of debt 19,261 10,454 Gain on sale of assets (4,173 ) (408 ) Changes in contingent consideration 1,672 (3,260 ) Stock-based compensation 12,540 10,379 Deferred income taxes, net (8,699 ) (21,960 ) Other (15,132 ) (18,329 ) Changes in operating assets and liabilities, net of effects of acquisitions and disposals: Accounts receivable 4,316 (8,714 ) Inventories (5,617 ) (19,904 ) Prepaid expenses and other current assets 1,184 1,636 Accounts payable and accrued expenses 17,390 (2,855 ) Income taxes receivable and payable, net   5,817     (8,297 ) Net cash provided by operating activities from continuing operations   301,598     176,760   Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (35,912 ) (45,566 ) Proceeds from sale of assets 9,792 408 Payments for businesses and intangibles acquired, net of cash acquired   (14,040 )   (63,451 ) Net cash used in investing activities from continuing operations   (40,160 )   (108,609 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 671,700 288,100 Reduction in borrowings (714,487 ) (303,627 ) Debt extinguishment, issuance and amendment fees (8,958 ) (9,017 ) Net proceeds from share based compensation plans and the related tax impacts 7,647 4,815 Payments to noncontrolling interest shareholders (464 ) (833 ) Payments for contingent consideration (133 ) (7,974 ) Payments for acquisition of noncontrolling interest (9,231 ) — Dividends paid   (43,980 )   (42,382 ) Net cash used in financing activities from continuing operations   (97,906 )   (70,918 ) Cash flows from discontinued operations: Net cash used in operating activities   (1,451 )   (1,954 ) Net cash used in discontinued operations   (1,451 )   (1,954 ) Effect of exchange rate changes on cash and cash equivalents   (988 )   (22,052 ) Net increase (decrease) in cash and cash equivalents 161,093 (26,773 ) Cash and cash equivalents at the beginning of the period   338,366     303,236   Cash and cash equivalents at the end of the period $ 499,459   $ 276,463     Non cash financing activities of continuing operations: Settlement and exchange of convertible notes with common or treasury stock $ 35,205 $ 62 Acquisition of treasury stock associated with settlement and exchange of convertible note hedge and warrant agreements $ 85,909 $ 125  

Teleflex IncorporatedJake ElguiczeTreasurer and Vice President of Investor Relations610-948-2836

Teleflex (NYSE:TFX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Teleflex Charts.
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Teleflex Charts.